CHLORAMBUCIL (CHL) is a biftunctioial alkylating agent commonly used in the treatment of advanced human cancers (Goodman & Gilman, 1975) . Althouglh available since the late 1950s, only recently have its metabolism (McLean et al., 1980 ) and disposition kinetics been described. Alberts et al. (1979) reported that after oral administration CHL rapidly appeared in the plasma and was eliminated with a disappearance half-life of -1 5 h. Phenylacetic acid mustard (PAAM), the major plasma metabolite, also appeared rapidly in the plasma, and had a disappearance half-life of 2-5 h. Because the plasma concentration-time product (CXT) for PAAM was 45%o larger than for CHL, PAAM could play an important role in the in vivo anticancer activity of CHL. In the present stuidies we report the in vitro anticancer activity of CHI, and its major metabolites in a soft-agar cloning system.
Chlorambucil (Kuramoto et al., 1972) . The cell lines were maintained in standard media (8226: RPMI-1 640, Hec I A: McCoys 5A GIBCO) enriched with L-glutamine (292 .tg/l00 ml), 1000 foetal calf serunm (heat-inactivated at 57°C for 1 h, GIBCO) and penicillin G-streptomycin (GIBCO). Cells were harvested by centrifugation, divided and resuspended in fresh medium 24-48 h before drug testing.
Drug sensitivity was tested in a simplified 2-layer soft-agar cloning system (Salmon et al., 1978 using the Hec IA cell line were 1.4% and 1.9%. This cell line required 3-8 ,ug/ml of CHL, PAAM and DCHL to achieve 70% inhibition of colony formation (Fig. 2) . Again, the monochloroethyl metabolite was less active, producing 30% inhibition of colony formation at a concentration of 20 ,g/ml.
Using an in vitro cloning system we have shown that CHL and its 2 bifunctional alkylating metabolites, PAAM and DCHL, have similar inhibitory effects on CFUs of 2 neoplastic human cell lines. The monofunctional alkylating metabolite was less active, requiring 10-20-fold drug concentrations to produce comparable inhibition of CFU. McLean et al. (1980) have described the metabolism of [3H] CHL in SpragueDawley rats (Fig. 3) . Initial metabolism appears to be through beta oxidation of the butyric acid side chain, leading to the unsaturated intermediate DCHL. This metabolic pathway is analogous to the mitochondral beta oxidation of fatty acids. Further oxidation to an acetic-acid side chain leads to the major plasma metabolite PAAM. Both this compound and the dehydro intermediate (DCHL) remain bifunctional alkylating agents, since there has been no alteration of the N-bis(2-chloroethyl) side chain. Further metabolism cleaves one of the 2-chloroethyl side chains yielding the major urinary metabolite monochloroethyl APAA, a monofunctional alkylating agent.
When administered orally to man, CHL is rapidly absorbed and metabolized, yielding high plasma concentrations of both CHL and PAAM (Alberts et al., 1979; McLean et al., 1979) . Although there are no significant differences in peak plasma concentrations, the plasma half-life for PAAM is longer than that of CHL. Hence, the area under the plasma disappearance curve (CXT) for PAAM is almost 45 % greater than that of CHL. Since CHL and PAAM have similar inhibitory effects on turnover CFUs. PAAM may be important in the in vivo anticancer activity of CHL.
